Register now!
  • Boston Scientific joins Avicenna Alliance

    As further evidence of the Alliance’s growing momentum, Avicenna Alliance is happy to announce the newest addition to its list of members: Boston Scientific.


    Find out more

  • Avicenna Alliance’s Secretary General to speak at Materialise World Summit 2017

    On the 20 and 21 April 2017 the Materialise World Summit (MWS) will take place, a two-day event which brings together stakeholders from various businesses and industries.


    Find out more

  • Avicenna Alliance –Review 2016

    A look back at the year 2016 reveals that it has been a very successful first year for the Avicenna Alliance.


In Silico turning Big Data into Personalized Medicine 

On 11 October 2016, European Parliament Brussels, MEPs Nicola Caputo (S&D) and Seán Kelly (EPP, Ireland) in cooperation with the Avicenna...

find out more ›

EC asks VPHi for input in Horizon 2020 Work Programme

The European Commission has requested that the Virtual Physiological Human Institute (VPHi), the Academic Research Membership of the Avicenna...

find out more ›

FDA to look towards Observer Status in Avicenna Alliance

The Avicenna Alliance has been in touch with the FDA on the issue of in silico medicine over the last number of months and has reached a new...

find out more ›

Avicenna Alliance review meeting with the European Commission

On 02 May 2016, Avicenna Alliance delegates met with representatives of DG Connect to discuss progress on in silico medicine in the 1st...

find out more ›

EC Appoints VPH to key stakeholder group

The European Commission has appointed the Virtual Physiological Human Institute (VPHi) to its eHealth Stakeholder Group. With VPHi representing 50% of the...

find out more ›

EMA Regulation Vote result – major gains for in silico

On 10 March 2016 the European Parliament through an overwhelming majority, voted in favour of requiring the EMA to take into account alternative...

find out more ›

EMA PRIME scheme – room for improvement

On 07 March 2016, the European Medicines Agency (EMA) launched their new Priority Medicines Scheme (PRIME) which aims to accelerate assessment of innovative...

find out more ›